Atenolol: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
imported>Robert Badgett
Line 36: Line 36:


==Dosage==
==Dosage==
For healthy adults, the starting dose recommended by the manufacturer is 50 mg orally once daily<ref name="isbn1-56363-703-0">{{cite book |author=Physicians Desk Reference |authorlink= |editor= |others= |title=Physicians' Desk Reference 1982: Library/Hospital Version (Physicians' Desk Reference (Pdr)) |edition=36th |language= |publisher=Medical Economics |location=Oradell, NJ |year=1982|origyear= |pages=1884 |quote= |isbn=0874898501 |oclc= |doi= |url= |accessdate=}}</ref> and the maximum dose is 100 mg orally once daily. ''However'', atenolol may require twice daily dosing<ref name="pmid18259123">{{cite journal |author=Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL |title=Comparative efficacy of two different beta-blockers on 24-hour blood pressure control |journal=J Clin Hypertens (Greenwich) |volume=10 |issue=2 |pages=112–8 |year=2008 |month=February |pmid=18259123 |doi=10.1111/j.1751-7176.2008.08021.x |url= |issn=}}</ref> The INVEST trial used atenolol twice a day if 50 mg once per day did not control pressure. In this study atenolol had similar outcomes to other [[antihypertensive agent]]s.<ref name="pmid14657064">{{cite journal |author=Pepine CJ, Handberg EM, Cooper-DeHoff RM, ''et al.'' |title=A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial |journal=JAMA |volume=290 |issue=21 |pages=2805–16 |year=2003 |month=December |pmid=14657064 |doi=10.1001/jama.290.21.2805 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=14657064 |issn=}}</ref>
For healthy adults, the starting dose recommended by the manufacturer is 50 mg orally once daily<ref name="isbn1-56363-703-0">{{cite book |author=Physicians Desk Reference |authorlink= |editor= |others= |title=Physicians' Desk Reference |edition=36th |language=English |publisher=Medical Economics |location=Oradell, NJ |year=1982|origyear= |pages=1884 |quote= |isbn=0874898501 |oclc= |doi= |url= |accessdate=}}</ref> and the maximum dose is 100 mg orally once daily. If the estimated creatinine clearance is less than 15 ml/min then the dose should be given every other day.<ref name="isbn1-56363-703-0"/> ''However'', atenolol may require twice daily dosing<ref name="pmid18259123">{{cite journal |author=Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL |title=Comparative efficacy of two different beta-blockers on 24-hour blood pressure control |journal=J Clin Hypertens (Greenwich) |volume=10 |issue=2 |pages=112–8 |year=2008 |month=February |pmid=18259123 |doi=10.1111/j.1751-7176.2008.08021.x |url= |issn=}}</ref> The INVEST trial used atenolol twice a day if 50 mg once per day did not control pressure. In this study atenolol had similar outcomes to other [[antihypertensive agent]]s.<ref name="pmid14657064">{{cite journal |author=Pepine CJ, Handberg EM, Cooper-DeHoff RM, ''et al.'' |title=A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial |journal=JAMA |volume=290 |issue=21 |pages=2805–16 |year=2003 |month=December |pmid=14657064 |doi=10.1001/jama.290.21.2805 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=14657064 |issn=}}</ref>


==Efficacy==
==Efficacy==

Revision as of 10:20, 15 July 2009

This article is a stub and thus not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Atenolol&printable=yes
This editable Main Article is under development and subject to a disclaimer.
Atenolol.png
atenolol
IUPAC name: see chemistry section
Synonyms:
Formula: C14H22N2O3
 Uses: hypertention;angina pectoris
 Properties: hydrophilic
 Hazards: see side effects & drug interactions
Mass (g/mol): CAS #:
266.34 29122-68-7


In medicine, atenolol is a cardioselective adrenergic beta-antagonist that is "possessing properties and potency similar to propranolol, but without a negative inotropic effect."[1] Atenolol is hydrophilic[2]

History

Atenolol was developed by the Stuart Company which was a division of Imperial Chemical Industries (ICI). ICI was renamed Zeneca in 1992. Atenolol received approval in the United States August 19, 1981.[3] According to drugstore.com, 90 days of generic 50 mg pills costs $17.99 in January, 2009.

Generic atenolol was available in 1988.[4]

Chemistry

Atenolol may defined by IUPAC nomenclature:

  • 4-[2'-hydroxy-3'-[(1-methylethyl)amino]propoxy-benzeneacetamide
  • Benzeneacetamide, 4-[2'-hydroxy-3'-[(1-methylethyl) amino] propoxy]- (according to [1])

It is a hydrophilic drug, with solubility in water equal to 26.5 mg/mL at 37ºC, with chemical formula C14H22N2O3 andmolecular mass 266.34 gram/mole for the free base form. It is freely soluble in strongly acidic solutions.

Metabolism

Atenolol is excreted unchanged in the kidneys. Elimination is dependent on the glomerular filtration rate. With normal renal function, the serum half-life is about 8 hours. While this means atenolol may need twice a day dosing for some diseases in which control of heart rate is important, atenolol can be used once a day for isolated hypertension because the central nervous system pharmacodynamic effect persists longer.

Atenolol is not metabolized in the liver by cytochrome P-450 2D6 allele.

Dosage

For healthy adults, the starting dose recommended by the manufacturer is 50 mg orally once daily[5] and the maximum dose is 100 mg orally once daily. If the estimated creatinine clearance is less than 15 ml/min then the dose should be given every other day.[5] However, atenolol may require twice daily dosing[6] The INVEST trial used atenolol twice a day if 50 mg once per day did not control pressure. In this study atenolol had similar outcomes to other antihypertensive agents.[7]

Efficacy

Coronary heart disease

Heart failure

Although atenolol has not received indication in the United States for the treatment of heart failure, two cohort studies suggest that the beta-blockers atenolol and carvedilol may be more effect than metoprolol for the treatment of heart failure.[8][9]

Randomized controlled trials by one research group also suggest atenolol might benefit.[10][11]

Hypertension

Atenolol may not reduce mortality as well as other antihypertensives according to a systematic review; however, this review did not compare atenolol against other adrenergic beta-antagonists and it is not clear whether all of the included trials allowed patients with active coronary heart disease who would have most benefitted from a adrenergic beta-antagonist.[12]

The INVEST trial used atenolol twice a day if 50 mg once per day did not control pressure. In this study atenolol had similar outcomes to other antihypertensive agents.[7]

External links

The most up-to-date information about Atenolol and other drugs can be found at the following sites.


References

  1. ↑ Anonymous (2024), Atenolol (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. ↑ Tuininga YS, Crijns HJ, Brouwer J, et al (December 1995). "Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients". Circulation 92 (12): 3415–23. PMID 8521562. [e]
  3. ↑ Drugs@FDA. U S Food and Drug Administration
  4. ↑ Drugs@FDA. U S Food and Drug Administration
  5. ↑ 5.0 5.1 Physicians Desk Reference (1982). Physicians' Desk Reference (in English), 36th. Oradell, NJ: Medical Economics, 1884. ISBN 0874898501. 
  6. ↑ Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL (February 2008). "Comparative efficacy of two different beta-blockers on 24-hour blood pressure control". J Clin Hypertens (Greenwich) 10 (2): 112–8. DOI:10.1111/j.1751-7176.2008.08021.x. PMID 18259123. Research Blogging.
  7. ↑ 7.0 7.1 Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. (December 2003). "A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial". JAMA 290 (21): 2805–16. DOI:10.1001/jama.290.21.2805. PMID 14657064. Research Blogging.
  8. ↑ Kramer JM, Curtis LH, Dupree CS, et al (December 2008). "Comparative effectiveness of beta-blockers in elderly patients with heart failure". Arch. Intern. Med. 168 (22): 2422–8; discussion 2428–32. DOI:10.1001/archinternmed.2008.511. PMID 19064824. Research Blogging.
  9. ↑ Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R (December 2008). "Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice". Arch. Intern. Med. 168 (22): 2415–21. DOI:10.1001/archinternmed.2008.506. PMID 19064823. Research Blogging.
  10. ↑ Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B, Stanek B (December 2000). "Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril". Eur. J. Heart Fail. 2 (4): 407–12. PMID 11113718. [e]
  11. ↑ Hülsmann M, Sturm B, Pacher R, et al (November 2001). "Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction". J. Heart Lung Transplant. 20 (11): 1174–80. PMID 11704477. [e]
  12. ↑ Carlberg B, Samuelsson O, Lindholm LH (2004). "Atenolol in hypertension: is it a wise choice?". Lancet 364 (9446): 1684–9. DOI:10.1016/S0140-6736(04)17355-8. PMID 15530629. Research Blogging.
Retrieved from "https://citizendium.org/wiki/index.php?title=Atenolol&oldid=569300"